Quintiles Library

Harnessing Vital Data Image
Featured White Paper

Harnessing vital data to inform an optimal market access strategy in the UK
Market access now demands closer collaboration between biopharma, payers and providers. In a climate where ongoing reimbursement of a drug relies on biopharma’s ability to demonstrate how it delivers value to the entire healthcare system, partnership working is essential. Outcomes audits should be seen as one of the most important tools available to biopharma. They deliver detailed action plans to both biopharma and the NHS, proposing improvements to the care pathway...


















































































Remove allSelected Topics:
    Press Release
    Research Triangle Park, NC – October 30, 2014 – Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) today reported its financial results for the third quarter ended September 30, 2014. 13.8% consolidated service revenue growth - Integrated Healthcare Services segment grew service revenues by 32.6% compared to the third quarter of 2013 Consolidated book-to-bill ratio of 1.42 results from 12.8% growth in net new business compared to the third quarter of 2013 Third quarter diluted adjusted EPS increased 22.6% to $0.65 per share compared to the third quarter of 2013 Third quarter GAAP reported diluted EPS increased 42.0% to $0.71 per share compared to the third quarter of 2013 Adjusted full year 2014 service revenue guidance of...
    Read More
    Fact Sheet
    Office 365 Exchange Online...
    Read More
    Press Release
    HOUSTON – October 28, 2014 – Modern Healthcare has ranked Encore, A Quintiles Company (formerly Encore Health Resources), in the top 10 of the publication’s 100 Best Places to Work in Healthcare for healthcare suppliers. Encore, a leader in the health-information analytics and technology consulting services focused on healthcare providers, has been recognized on this coveted list every year since the company began operations in 2009. “I am tremendously proud of the company and our employees who truly make Encore a great place to work,” said Dana Sellers, CEO, Encore, A Quintiles Company. “This ranking is particularly special because it’s based almost entirely on information from our own staff – the people who have rolled up their sleeves, done great work for our clients and have helped...
    Read More
    Video
    In this series of Site Training & E-Learning Program (STEP) videos, Quintiles shares what we think may be useful for Site Coordinators managing clinical trials to know. #1 – Knowledgeable #2 – Proactive #3 – Resourcefulness #4 – Building Rapport #5 –...
    White Paper
    Life Science companies that stand to thrive in the increasingly evidence-based marketplace will be those who embrace value-based healthcare and catalyze the system movement toward enhanced outcomes. By understanding the interdependent trends, firms can drive improvements in population health outcomes while navigating these transformational...
    Explore More
    Media Coverage
    On Tuesday, Dr. Jeff Spaeder, Quintiles Chief Medical and Scientific Officer, was interviewed via satellite by Jim Cramer, CNBC’s host of the investment segment, "Mad Money," which airs daily in the US, New Zealand and Australia. As host of Mad Money, Cramer works to guide the more than 166,000 cable viewers through the confusing jungle of Wall Street investing. According to Cramer, the Ebola crisis is causing uncertainty among investors so he wanted insights from the experts in drug development. This is the player to use for single videos on Q.com ...
    Read More
    Presentation
    Whether you are an investigator, trial sponsor or manufacturer of products or devices, compliance with safety reporting requirements to Chinese FDA has never been so critical on the heels of tightening regulations and increased scrutiny. In this short presentation, Deirdre McCarthy, Senior Benefit-Risk Management Director at Quintiles, discusses clinical trial safety reporting requirements for both sponsors and investigators, with a special segment on vaccine safety reporting. She also covers post-marketing requirements before finishing with an update on a recent medical device regulation in...
    Explore More
    Fact Sheet
    Quintiles Laboratory Facility in Pretoria, South Africa was established in 1999. This BSL3, CAP-accredited, full-service laboratory includes capabilities spanning: Pre-analytical,  Analytical, Project Services, Specimen Management and Storage, Clinic supplies, and Logistics support.   These end-to-end services are tailored to meet the complexities of providing clinical trial sites support in South Africa, and are set up to help ensure timely turn-around of testing and result reporting, safe handling and transport of samples, and best-in-class project...
    Read More
    Presentation
    This webinar, presented by Dr. Louise Parmenter, PhD, Global Head of Operations, Epidemiology & Outcomes Research, Real-World & Late Phase Research and Ms. Anke van Engen, MSc, Senior Consulting Director, Practice Leader HTA Solutions at Quintiles, addresses how to optimize your real world evidence research by seeking first to understand the needs of the broad spectrum of decision-makers and then marrying these needs with insights into real-world data access and availability. This webinar focuses on the challenge for sponsors to meet a diversity of evidentiary needs in a complex and changing market. The webinar includes case examples, and our recommended approach to drive real-world-evidence, using real-world insights, for a more impactful and streamlined portfolio of real-world...
    Explore More
    White Paper
    Liver cancer is a leading cause of cancer-related death worldwide. It is the fifth most common cancer in men (554,000 cases, 7.5% of the total) and the ninth in women (228,000 cases, 3.4%). In men, the regions of high incidence are Eastern and South-Eastern Asia (ASRs 31.9 and 22.2 respectively). In women, the rates are generally much lower. Liver cancer is the second most common cause of death from cancer worldwide, estimated to be responsible for nearly 746,000 deaths in 2012 (9.1% of the total) and prognosis is very poor. Hepatocellular carcinoma (HCC) is the most common type of liver cancer. The incidence of HCC is expected to rise in the United States and across the world, given the increasing prevalence of hepatitis C and B infections, alcohol consumption, diabetes, toxin exposure,...
    Explore More
    White Paper
    In clinical trials, maintaining acceptable data retention rates is a challenging task, especially in long-term follow-up studies. The US Food and Drug Administration (FDA) has declined certain drug applications for approval largely due to concerns over missing follow-up safety data and methodological issues with the trials in the drugs’ clinical development programs. This emphasizes the critical importance of a robust process for obtaining data retention and survival status information for all patients enrolled in an investigational trial.  With key milestones on the line, the Quintiles project team for the TRILOGY Acute Coronary Syndromes (ACS) clinical trial developed and implemented a robust data retention process to ensure maximum control of subject retention during the study. At...
    Explore More
    White Paper
    In the past, when smaller U.S. biopharmaceutical companies wanted to enter the European market, they had two choices – go it alone, an approach that includes substantial cost, risk and uncertainty; or out-license the product to another company, which required them to give up control of the product and perhaps lessen the long-term value of their portfolio. Now they have a third option. By partnering with a well-established outsourcing specialist they can overcome much of the risk while taking advantage of a vast network of human resources and infrastructure across Europe. Through these partnerships, smaller biopharma companies can more efficiently get their drug into the market – without giving up strategic control or long-term value.  This paper outlines the challenges North American...
    Explore More
    Fact Sheet
    Healthcare systems across Asia Pacific are evolving - as expenses rise alongside improvements in care, payers are increasingly demanding proof of value from new medicines. For today’s drug developers, the emphasis has shifted from “time to market” to “time to access.” By clearly communicating a strategic and cohesive value message to key stakeholders, the path to market access can be navigated more effectively and efficiently. Discover how Medical Science Liaisons (MSLs) can be an integral part of your team and gain a deeper insight into: The difference between a traditional sales representative and a MSL How MSLs can help to prepare the market during the pre-launch phase Effectively engaging with key opinion leaders (KOLs) and stakeholders Best practice and key success...
    Read More
    Fact Sheet
    The market access challenge requires a successful response to multiple stakeholders from different countries – each with their own needs and requirements. Anticipating these diverse demands and developing the necessary evidence requires a nuanced understanding of the dynamic payer environments you must navigate. Quintiles’ HTA Accelerator offers an integrated solution providing payer insights for launch...
    Read More
    Fact Sheet
    Getting a clinical trial off to the right start is vital. However, across the industry, trials face multiple delays and 20% of sites recruit zero patients, due to the scarcity of good information. An optimized approach to start-up that leverages data, analytics, process expertise and site relationships has enabled faster start-up. See how Quintiles’ can establish a solid route to trial execution...
    Read More
    Press Release
    RESEARCH TRIANGLE PARK, NC – October 14, 2014 – Quintiles today announced that the company was awarded the Society for Clinical Research Sites’ (SCRS) 2014 Clinical Research Organization (CRO) Eagle Award. The award, which recognizes outstanding leadership, professionalism, integrity, passion and dedication, was presented during the annual SCRS Site Solutions Summit. "It is such an honor to be recognized again and receive this award for the second year in a row,” said Lindy Jones, senior vice president, Integrated Site Services, Quintiles. “Our ambition of transforming clinical development and accelerating pipelines to achieve better patient outcomes is only possible through the dedication and hard work of our investigators and sites. I would like to thank the investigators who voted for...
    Read More
    White Paper
    How is next generation sequencing (NGS) transforming oncology clinical development and treatments for cancer?  Read this recent whitepaper to learn how.  The overall goal in the era of emerging precision is to develop cancer medications that attack the right target, or targets, in the right disease, in the right patient, at the right dose to obtain the desired outcome.  Several targeted therapies have successfully been developed and the pipeline of additional precision medicines looks promising.  But how can the drug development community better capitalize on sophisticated genomics-based tools available to help transform clinical development and cancer care in the coming decade? This paper investigates fundamentals and key considerations to integrating NGS in the clinical development of...
    Explore More
    Presentation
    Biopharma’s success in the new healthcare economy is predicated on one simple principle: prove the value of your treatments or risk losing market share and profits. Healthcare costs are climbing, regulators around the globe are requiring more information, and both providers and payers have higher expectations for a medical treatment’s proof of value before prescribing or paying for those treatments. These quality, cost and outcome driven imperatives must also incorporate efficacy, safety, benefits as compared with competing products, and overall improved quality of life.  Download the presentation given by Paul Sutton, Director of Outcomes at Quintiles Commercial UK, entitled: “Value is the target: aligning value for payers to pharma”.  Paul Sutton leads the design and implementation of...
    Explore More